Acessibilidade / Reportar erro

Darier’s disease: treatment with topical sodium diclofenac 3% gel Study conducted at the General Outpatient Clinic of the Dermatology Service, Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Dear Editor,

A 32-year-old male patient came to the authors outpatient clinic with a previous history of epilepsy and cognitive impairment, using carbamazepine and a clinical and histopathological diagnosis of Darier's disease for eight years. On physical examination, he had multiple erythematous-brown, keratotic papules, some of them crusted, located on the dorsal region, shoulders and anterior thorax (Fig. 1). He had previously used topical keratolytics, corticosteroids and retinoids, in addition to systemic antibiotics, without achieving lesion control. Systemic retinoids were avoided due to possible drug interactions (carbamazepine).

Figure 1
(A) Dorsal region ‒ before treatment. (B) Right scapular region, before treatment

After reviewing the literature, the authors found some reports on the use of topical sodium diclofenac in Darier's disease. They chose to start with 3% sodium diclofenac and 2.5% hyaluronic acid in natrosol gel, applied twice a day only on the affected areas on the left side of the body, for eight weeks. After significant improvement of the lesions, the patient was instructed to apply it on all affected areas, twice a day. He denied local or systemic adverse reactions during medication use and no laboratory changes were observed during this period. After four months of treatment, he showed significant lesion regression, with post-inflammatory hypo- and hyperchromic macules and the presence of a few residual keratotic papules (Fig. 2). Medication use was reduced to once a day for another four weeks and the treatment was discontinued, with good clinical control maintained since then.

Figure 2
(A) Dorsal region, four months after starting treatment. (B) Detail of the dorsal region, right scapular region after treatment

Darier's disease occurs due to a mutation in the ATP2A2 gene, which encodes a protein involved in epidermal differentiation and intercellular communication called SERCA2B, leading to impaired SERCA21 function.11 Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22.,22 Millan-Parrilla F, Rodrigo-Nicolas B, Moles-Poveda P, Armengot-Carbo M, Quecedo-Estebanez E, Gimeno-Carpio E. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol. 2014;70:89-90. It manifests as erythematous-brown, keratotic-crusted papules, in seborrheic areas of the trunk, scalp, face, and neck associated with a foul odor and pruritus.11 Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22. Ungual changes may also be observed, such as erythematous and white longitudinal bands, longitudinal fissures, subungual keratosis, and brittleness, forming “V”-shaped notches.11 Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22.

Treatment of Darier's disease includes general measures such as wearing light clothing and sunscreen protection; use of topical medications, such as keratolytics, corticoids, retinoids, tacrolimus, and 5-fluorouracil; and systemic drugs such as acitretin, isotretinoin, or cyclosporine. Surgical and photodynamic therapy can also be performed.11 Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22.

Sodium diclofenac 3% was recently described as a therapeutic option in Darier's disease.22 Millan-Parrilla F, Rodrigo-Nicolas B, Moles-Poveda P, Armengot-Carbo M, Quecedo-Estebanez E, Gimeno-Carpio E. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol. 2014;70:89-90.

3 Santos-Alarcon S, Sanchis-Sanchez C, Mateu-Puchades A. Diclofenac sodium 3% gel for Darier’s disease treatment. Dermatol Online J. 2016;22:17-20.
-44 Palacios-Alvarez I, Andres-Ramos I, Silva MY, Simal G. Treatment of Darier’s disease with diclofenac sodium 3% gel. Dermatol Ther. 2017;30:1-3. Its mechanism of action occurs by inhibiting cyclooxygenase-2, resulting in the suppression of prostaglandin E2 activity, which in turn downregulates the ATP2A2 gene. This leads to the normalization of SERCA2 levels in keratinocytes.11 Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22. Its use is combined with hyaluronic acid 2.5%, which acts by maintaining the drug on the epidermis and superficial dermis, with better local action and less systemic absorption.55 Nelson CG. Diclofenac gel in the treatment of actinic keratosis. Ther Clin Risk Manag. 2011;7:207-11.

  • Financial support
    None declared.
  • Study conducted at the General Outpatient Clinic of the Dermatology Service, Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

References

  • 1
    Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERC2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol. 2011;166:1017-22.
  • 2
    Millan-Parrilla F, Rodrigo-Nicolas B, Moles-Poveda P, Armengot-Carbo M, Quecedo-Estebanez E, Gimeno-Carpio E. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol. 2014;70:89-90.
  • 3
    Santos-Alarcon S, Sanchis-Sanchez C, Mateu-Puchades A. Diclofenac sodium 3% gel for Darier’s disease treatment. Dermatol Online J. 2016;22:17-20.
  • 4
    Palacios-Alvarez I, Andres-Ramos I, Silva MY, Simal G. Treatment of Darier’s disease with diclofenac sodium 3% gel. Dermatol Ther. 2017;30:1-3.
  • 5
    Nelson CG. Diclofenac gel in the treatment of actinic keratosis. Ther Clin Risk Manag. 2011;7:207-11.

Publication Dates

  • Publication in this collection
    03 Nov 2023
  • Date of issue
    Nov-Dec 2023

History

  • Received
    29 Dec 2021
  • Accepted
    31 Jan 2022
  • Published
    29 June 2023
Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br